membranoprolferative gn

29
Membranoprolferative GN

Upload: mohamed-elamin-awad

Post on 14-Dec-2014

206 views

Category:

Health & Medicine


0 download

DESCRIPTION

MPGN, MCGN presentation, diagnosis and update management

TRANSCRIPT

Page 1: Membranoprolferative GN

Membranoprolferative GN

Page 2: Membranoprolferative GN

Occur primarily children & young adults.Definition is based on :Mesangial & endothelial cell proliferationExpansion of mesangial matrix Thickened peripheral capillary wallMesangial interposition into the Cap wall

Page 3: Membranoprolferative GN

Subendothelial deposits characteristic of membranoproliferative glomerulonephritis Type I

Page 4: Membranoprolferative GN

MPGN I

Silver stain

Mesangial proliferation and mesangial interposition beneath the capillary loop endothelial cells with formation of "double contours"

Page 5: Membranoprolferative GN

MPGN I

Electron microscopy

The deposits are subendothelial and mesangial. There is duplication of the capillary loop basement membrane between the deposits and interposed mesangium, and the endothelial cells

Page 6: Membranoprolferative GN

MPGN I

Direct immunofluorescence

Subendothelial and mesangial deposits of IgG and C3

Page 7: Membranoprolferative GN

MPGN II

Electron microscopy

The capillary loops contain interrupted linear electron densities in the subendothelial aspect of the basement membrane.

Page 8: Membranoprolferative GN

MPGN II

Direct immunofluorescence

There is bright peripheral loop staining with antibody to C3 as well as mesangial staining. Staining for immunoglobulins is often less intense

Page 9: Membranoprolferative GN

MPGN III

Electron microscopy

There are prominent mesangial, subendothelial, and subepithelial electon dense deposits

Page 10: Membranoprolferative GN

Mesangial expansion and proliferation

Thickend membrane

Page 11: Membranoprolferative GN

Primary or secondary which is more common.

Idiopathic type : I , II , III depending on: IF staining ,ultrastructural appearance & complement profiles.Hypocomplementaemia is characteristic due to decrease synthesis & consumption.

Page 12: Membranoprolferative GN
Page 13: Membranoprolferative GN

Type I

- Diagnosis by exclusion. - There is discrete deposition in the

mesangium & subendothelial space.

- NS progressive ESRD 50%,90%in10,20ys

- non NS 85% renal survival at 10ys

- 30 – 70 % recurrence in RXT

Page 14: Membranoprolferative GN
Page 15: Membranoprolferative GN
Page 16: Membranoprolferative GN

Type II Dense deposits disease

Deposition along the memb, tubules & boman`s capsule.

- IF +ve for C3 –ve for Ig & complexes- Tram track C3 deposition - High rate of recurrence in RXT 50 – 100 %

Page 17: Membranoprolferative GN
Page 18: Membranoprolferative GN

Type III

Imcomplex disease.

** C3,C5 & properdin deposition.

** Recurrence is unknown in RXT

Page 19: Membranoprolferative GN
Page 20: Membranoprolferative GN

Presentation

Asymptomatic proteinuria & haematouria 20 – 30 %NS 40 – 67 %Acute nephritic syndrome 16 – 30 %Gross haematouria 10 – 20 %Azotaemia

Page 21: Membranoprolferative GN

Diffuse glomerulonephritis

Inflamatory cells infiltrate in glomeruli & interstitium

Page 22: Membranoprolferative GN
Page 23: Membranoprolferative GN
Page 24: Membranoprolferative GN

Treatment

Reserved for those with:

– proteinuria >3gm/day

- interstitial disease

- impaired renal function

Page 25: Membranoprolferative GN

Diet

Normal renal function :normal protein 1 gm/kg/day +urine lossRenal impairment :0.65 – 0.8 gm/day + urine loss Low cholesterol diet

Page 26: Membranoprolferative GN

Non specific treatment

BP control Oedema Hyperlipidaemia < 100 mg/dl LDLInfection Thromboembolism

Page 27: Membranoprolferative GN

Drug treatment

Prednisolone :2 mg/kg every other day for 1yr then tapered to maintenance of20 mg every other day for 3 – 10 ys120 mg on alternate days for12–16 /52 with follow up .After response taper to 20 – 30 mg alternate days for several ys.

Page 28: Membranoprolferative GN

Antiplatelets : Can slow the progression

*-* Aspirin 975mg/day + dipyridamol 225 mg/day OR

*-* Asprin 500 mg/day + dipyridamol 75 mg/day for 3ys.

Page 29: Membranoprolferative GN

Cytotoxics : It is not felt that addition of

this group would provide further benefits.